Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-102 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05008445Phase 2Terminated
- Sponsor
- LaNova Medicines
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tecotabart in solid tumor (advanced stage), gastric cancer (GC), gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), biliary tract cancer (BTC), sponsored by LaNova Medicines. Started Oct 2021; status: terminated.
02
Drugs
tecotabart
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05008445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008445.